A team of researchers working in Singapore has found that human T cells actually target dengue viral infections in the skin, which is the normal infection site. In their paper published in the journal Science Translational Medicine, the team describes how they found that T cells in patients were able to recognize the dengue virus and also expressed a marker that caused them to move to the skin.
Dengue (fever) is a mosquito borne tropical disease that strikes approximately 100 million people every year. It is characterized by fever, muscle and joint pain and headaches along with a skin rash. People stricken typically survive unless the disease develops into hemorrhagic fever.
Though scientists have been working to find a cure for the disease for thousands of years, thus far, they have not found much success. Treatment typically focuses on relieving symptoms. In this new effort, the researchers focused on what T cellsin the human body do once a mosquito deposits a viral load into the skin.
The team started by looking at tissue specific markers—ID tags that indicate where they are to go when the immune system is called into action.
They found that certain T cells were dengue specific and to their surprise they were not indicators that would lead the cells to the GI track, which for patients, can be a viral hot spot (causing pain and bleeding). Instead, the markers led the T cells to the skin, which would be the site of the initial infection—and which would of course allow the T cells to combat the virus right from the get go.
The team was able to demonstrate that the T cells recognized the virus when their paths crossed and that they were capable of calling for an immune response when it happened, which typically meant attacking infected cells and making them burst. The findings by the team might eventually explain why patients develop a week-long rash—it could be the result of the battle between the virus and T cells raging shortly after the initial infection. The hope, however, is that the new findings might lead to a better vaccine, perhaps one that is directed at infections still confined to the skin.
Source: Medical Xpress